BioCheetah is a Singapore-based, Agency Science Technology and Research(A*STAR)-Institute of Molecular and Cell Biology(IMCB) spin-off company. It is primarily set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. There are several clinical trials for clinical validation of the bladder cancer diagnostic products is currently underway locally and with several hospitals worldwide.